anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In general, the adverse reactions observed in children and adolescents during the clinical trials were similar to those in the adult population with few exceptions. Increases in systolic and diastolic blood pressure occurred in children and adolescents and did not occur in adults. Orthostatic hypotension occurred more frequently in adults (4 to 7%) compared to children and adolescents (< 1%). 

Schizophrenia  Safety and effectiveness of quetiapine in pediatric patients less than 13 years of age with schizophrenia have not been established. 

Maintenance The safety and effectiveness of quetiapine in the maintenance treatment of bipolar disorder has not been established in pediatric patients less than 18 years of age. The safety and effectiveness of quetiapine in the maintenance treatment of schizophrenia has not been established in any patient population, including pediatric patients. 

Bipolar Mania  Safety and effectiveness of quetiapine in pediatric patients less than 10 years of age with bipolar mania have not been established. 

Bipolar Depression Safety and effectiveness of quetiapine in pediatric patients less than 18 years of age with bipolar depression have not been established. 

Pediatric use information in patients (13 to 17 years of age) with schizophrenia, and patients (10 to 17 years of age) with bipolar mania is approved for AstraZeneca Pharmaceuticals LP’s quetiapine fumarate drug product labeling. However, due to AstraZeneca Pharmaceuticals LP’s marketing exclusivity rights; this drug product is not labeled for such use in those patients.
BACKGROUND: Sleep remains a cornerstone for sociopsychological well-being, but it is in decline, especially among today's youth. Simultaneously, engagement with social media is escalating. Research has identified a link between social networking sites use and sleep problems; however, the nature and direction of the relations remain obscure. Therefore, it is imperative to pursue longitudinal research to elucidate this correlation and guide suitable intervention practices. The present study aimed to examine the reciprocal relationship between social networking sites use and sleep problems.
METHODS: By adopting a three-stage cross-lagged design across four time points, assessment results from 194 university students were gathered at four-week intervals.
RESULTS: The findings indicate that (1) Social networking sites use was significantly greater in females than in males at all four time points, while sleep problems were significantly greater in females than in males at Time 3 and Time 4. (2) Sleep problems at the second time point serve as a positive predictor of subsequent social networking sites use at the third time point. (3) Social networking sites use at the initial time point could marginally significantly predict sleep problems at the fourth time point.
CONCLUSIONS: This study elucidates the dynamic relationship between social networking sites use and sleep problems across an academic term, suggesting the need for temporally tailored interventions.
PURPOSE: To obtain a hair cosmetic having excellent conditioning effect on the hair and excellent in usability, by using a specific silicone-modified polymer and cationic surfactant(s). CONSTITUTION: This hair cosmetic contains in the whole system 0.1-10wt.% of a combination of at least one kind of cationic surfactant with a silicone- modified polymer prepared by reaction between an amino group-contg. polysiloxane of the formula (A is OH, an alkoxyl or amino group-contg. alkyl; R is an alkyl or OH; Q is an amino group-contg. alkyl; (m) and (n) are each 0-3; (x) is 30-400; (y) is 1-3) and an anionic polymer followed by neutralizing the reaction product with an alkaline compound so as to be 60-150% in neutralization degree. Besides, it is recommended that this system be incorporated with at least one kind of 14-22C straight-chain alkyl-bearing higher alcohol. The anionic polymer is esp. pref. a carboxyl-contg. polymer. The cationic surfactant is e.g. an alkyltrimethylammonium chloride.
As with all therapeutic proteins, there is a potential for immunogenicity. The clinical significance of antibodies to Kepivance is unknown but may include decreased activity and/or cross reactivity with other members of the FGF family of growth factors. 

In clinical trials, serum samples from patients treated with Kepivance were tested for antibodies to Kepivance using an electrochemiluminescence-based binding assay. Twelve of 645 patients (2%) tested positive; none had evidence of neutralizing activity in a cell-based assay. 

The incidence of antibody positivity is highly dependent on the specific assay and its sensitivity. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including sample handling, timing of sample collection, concomitant medications and underlying disease. For these reasons, comparison of the incidence of antibodies to Kepivance with the incidence of antibodies to other products may be misleading.
We performed a randomized prospective interventional trial where the Interventional group had immunosuppression modified according to ImmuKnow values. Immunosuppression was decreased by 25% if ImmuKnow values were less than 130 ng/mL ATP. Similarly, immunosuppression was increased by 25% if ImmuKnow values were greater than 450 ng/mL ATP. Immunosuppression of the Control group was managed by the Standard of Care at our institution. ImmuKnow was performed before liver transplant, after surgery and at each clinic visit with the approximate schedule: day 1; weekly, weeks 1-4; week 6; week 8; monthly, months 3-6; and months 9 and 12. ImmuKnow testing was repeated within 7 days of a suspected/confirmed rejection or infection and again within 1 week of resolution.
Participants will receive matching placebo orally once daily for 6 weeks during the DB treatment phase in Part 1 of the study. Participants who do not proceed to Part 2 of the study will undergo a post-treatment follow-up phase, after the DB treatment phase in Part 1 and will continue to take their single baseline SSRI/SNRI antidepressant throughout the study.
Critical care rehabilitation is an essential component of treating critically ill patients. Implementing early rehabilitation is safe and feasible, with benefits and early rehabilitation is both safe and feasible, with benefits far outweighing potential risks. An individualized rehabilitation plan is necessary for initiating early rehabilitation treatment. This includes identifying the rehabilitation needs of critically ill patients, timely seizing opportunities for rehabilitation intervention, and implementing safe rehabilitation measures through position training, exercise training, respiratory training, and monitoring the rehabilitation process. There remains considerable heterogeneity in the clinical practice of early rehabilitation treatment for critically ill patients. This article provides an updated overview of evidence-based medicine for early rehabilitation treatment of critically ill patients, aiming to offer a reference for clinical medical staff in formulating critical care rehabilitation treatment strategies for these patients.
A method for presenting therapy insights that includes pre-generated content at an electronic device. The method comprising, at a device with one or more processors, memory and a display, displaying, on the display, and insulin therapy data. The therapy insight corresponding to a person with diabetes (PWD). The therapy insight generated based in part on the insulin therapy data of the PWD. The therapy insight includes pre-generated content. The pre-generated content includes clinical advice of insulin-based management of diabetes associated with the PWD.
BACKGROUND: Direct browlift is useful but leaves a scar above the brow. We proposed a dual-plane browlift to avoid facial scarring while effectively resolving brow ptosis in young and young adult patients.
METHODS: Seven patients with facial palsy underwent dual-plane browlift between July 2018 and June 2022. The mean postoperative follow-up period was 31.9 months. Skin resection at the hairline was combined with subcutaneous dissection down to the inferior margin of the brow to "lift" the brow. Fascia lata strips were fixed to the dermis just inferior to the eyebrow to "hold" the brow, and the strips were suspended upward through the subperiosteal tunnel and fixed to the periosteum. Brow height was compared before and after the procedure and with the contralateral side.
RESULTS: The reported complications included slight hematoma at the recipient site, temporary difficulty in closing the eye, and seroma at the fascia donor site. The paralyzed side showed significant differences between the preoperative period and postoperative months (POM) 3, 6, and 12, but differences were not shown in the intervals between POM 3 and 6, 6 and 12, or 3 and 12. The difference in eyebrow height between the paralyzed and nonparalyzed sides was significant preoperatively but not at POM 3, 6, or 12. All scars matured well, and the fascia silhouette was not visible in the forehead region.
CONCLUSIONS: Dual-plane browlift enables rigid suspension using the fascia lata and excises flaccid skin without leaving facial scars, yielding excellent cosmetic quality and stable long-term outcomes.
Patients with a severe traumatic brain injury (sTBI) were included after written consent from next-to kin. The injury was considered as severe if having a Glasgow coma scale of 8 or less. Within 48h of trauma patients were included from the neurointensive care unit at Sahlgrenska university hospital, Gothenburg during 2000-2004. Patients were intubated and had a ventricular catheter. All patients were treated in accordance with the Lund Concept. Samples from ventricular cerebrospinal fluid (CSF) and blood was collected, during the first 3 weeks, then prepared for storage and later analyzed. Samples were stored in -70 degrees Celsius until analyzed. 1 year after trauma patients were assessed according to Glasgow outcome scale (GOS), NIHSS and Barthels Index. 10-15 years after trauma an evaluation of GOS by phone was repeated. Biomarkers such as Neurofilament light, Glial fibrillary acidic protein, Tau among others is analyzed in serum and CSF. Further, patients APOE genotype was explored. The investigators hypothesizes that higher concentrations of these biomarkers both in serum and CSF relate to worse 1-year and 10-15 year outcome after a severe traumatic brain injury. Further, patients that have the gene APOE4 is predisposed to worse 1 year and 10-15 year outcome after a sTBI. The investigators further want to explore the dynamics of these biomarkers in serum and CSF in the acute phase after trauma and if these biomarkers gave any prognostic value to on outcome (mortality and functional) 1-year and 10-15 years after trauma.
Clinical Studies

In two studies (protocol numbers KU-620-001 [Study 1] and KU-620-002 [Study 2]), the safety and efficacy of edex® were evaluated in 347 men with a diagnosis of erectile dysfunction due to vasculogenic, neurogenic and/or mixed etiology. Each study consisted of three phases: an in-office dose-titration phase, a two-week double-blind cross-over phase at home, and an open-label at home treatment phase that lasted for 12 months (Study 1) or six months (Study 2).

During the dose-titration phase, individualized optimum doses of edex® were established. Erectile response was measured by the Buckling Test to assess axial penile rigidity. A positive Buckling Test was achieved if the erect penis was able to support an axial load of 1.0 kg without buckling of the penile shaft. During the subsequent two-week double-blind, cross-over phase, patients self-injected edex® or placebo at home. Thereafter, patients continued to perform self-injections of open-label edex® for six or 12 months, and the occurrence of an erection sufficient for sexual intercourse was documented following each injection.
The imidazopyridines compounds of the present invention are serotonergic 5-HT3? antagonists. As such they are useful for the treatment of humans and animals wherein antagonism of 5-HT3? receptors is beneficial. Therapy is indicated for, but not limited to, the treatment of anxiety, psychoses, depression (especially depression accompanied by anxiety), cognitive disorders, substance abuse dependence and withdrawal, gastrointestinal motility disturbancies (including esophageal reflux, dyspepsia, gastric stasis, irritable bowel syndrome), emesis caused by chemotherapeutic agents, and visceral pain. Additionally, the compounds of the present invention may find utility as enhancers of nasal absorption of bioactive compounds.
PURPOSE: A rotating nano wire and a method for inducing cell eradication using the same are provided to rotates the nano wire inserted in the cell in a magnetic field application process by using a magnetic nano wire with a dipole. CONSTITUTION: A composition for cell eradication includes a magnetic nano wire with a dipole. The nano wire is composed of a metal nano wire or a magnetic material nano wire. The metal is formed by gold, platinum, palladium, copper, aluminum or their alloy. The magnetic material is composed of nickel, cobalt, iron, gadolinium, their alloy or their oxide. The dipole is formed on both ends of the nano wires.
The invention belongs to Chinese medicine preparation technical field, and in particular to a kind of concocting method of sealwort.The concocting method of the sealwort is comprised the following steps：A. select：Fresh sealwort of the impurity content less than 3%, without going mouldy, without rotting is chosen, it is standby；B. cut：The sealwort of the thickness >=5cm that will be selected is cut to thickness for 2 4cm；C. clean：Sealwort after classification is cleaned to free from admixture；D. cut into slices：By the sealwort section after cleaning；E. steam：Sealwort steams 3 4h to the saturating heart of medicinal material after section, interior without the white heart；F. dry：In dry-bulb temperature it will be 68 73 DEG C by the sealwort of boiling, humidity temperature is to dry 35 40h to moisture≤15.0% under the conditions of 14 17 DEG C.Herein described sealwort concocting method is simple and reliable, time-consuming and manpower.
This group will receive pre-operative opioid education, Exparel injection (liposomal bupivacaine, with bupivacaine, epinephrine and bicarbonate), and would not receive a prescription for opioids. This injection will be administered as 10cc injected in the operative field, consisting of \~5cc of Exparel (liposomal bupivacaine), \~5cc of bupivacaine, and \~1cc epinephrine. Pain scores and medication usage will be tracked for three days post operatively to assess the validity and efficacy of differing pain management strategies.
XTR006 is a 18F-labeled PET tracer, for the quantification of neurofibrillary tangle (NFT) deposition in the brain. Brain NFT deposition is a pathologic finding in Alzheimer's Disease (AD), with brain NFT density shown to correlate with the severity of cognitive impairment in AD. This Phase I study will be open-labeled, nonrandomized, single center study. Enrolled 10 healthy elderly Chinese volunteers who meet all of the inclusion and none of the exclusion criteria. Subjects will receive 8-10mCi of XTR006 via IV injection. Safety and tolerability will be observed. Biodistribution, pharmacokinetics, and dosimetry will be investigated.
The present invention relates to the technical field of biotechnologies, and in particular, to an anti-PD-1 single-domain antibody. The present invention provides an anti-PD-1 single-domain antibody. Complementarity determining regions (CDR) of the anti-PD-1 single-domain antibody comprise a CDR1 having an amino acid sequence as shown in one of SEQ ID Nos. 5 and 6, a CDR2 having an amino acid sequence as shown in one of SEQ ID Nos. 9-12, and a CDR3 having an amino acid sequence as shown in one of SEQ ID Nos. 17-21. The anti-PD-1 single-domain antibody provided in the present invention has a capability of specifically binding to PD-1, and can be used for further constructing a fusion protein, etc. The constructed fusion protein can also improve IFN-γ and/or IL-2 expression in T lymphocytes. The anti-PD-1 single-domain antibody can effectively inhibit the growth of tumors, and has a good industrialization prospect.
PURPOSE:To obtain an alopecia-preventing agent and trichogenous agent exhibiting excellent trichogenous effect by using cholera toxin as an active component. CONSTITUTION:A cholera toxin is used as an active component. It is administered preferably by parenteral administration such as subcutaneous injection and local application and the amount of the active component is 1ng to 1mug. The agent exhibits remarkable dilation action on local vessel, hair- generation promoting action and trichogenous action at the applied part and is effective as an alopecia-preventing agent and trichogenous agent. Cholera toxin is bonded to a receptor on the cell membrane of hair follicle to activate adenylic acid cyclase immediately under the cell membrane and vigorously produce cyclic adenosine monophosphate(cAMP) from adenosine triphosphate(ATP) in a cell. Energy is generated by the decomposition of ATP to form cAMP and the generated energy promotes the function of hair follicle, prevents the fallingoff of hair and promotes the hair generation.
The invention provides a cowpea chlorotic mottle virus-polypeptide compound and application thereof in osteoporosis treatment, belonging to the technical field of biological medicines. The compound is obtained by grafting polypeptide on the surface of cowpea chlorotic mottle virus; the polypeptide is an amino acid sequence shown as SEQ ID NO. 1. The compound of the present invention can effectively inhibit the formation and differentiation of osteoclasts, can effectively improve the bone mass and bone quality of osteoporosis, and is used for preventing and/or treating osteoporosis. In addition, the compound has strong safety and no cytotoxicity, can reduce the side effect caused by completely blocking a RANKL-RANK signal channel, and has no obvious side effect on organs such as heart, liver, spleen, lung, kidney and the like. The compound has the advantages of safety, no toxicity, stability, good effect and the like, and has good application prospect in the aspect of treating osteoporosis.
546,865. Vitamins. POTTS, H. E. (Distillation Products, Inc.). Jan. 31, 1941, No. 1275. [Class 2 (iii)] Tocopherol is obtained from a sludge or scum produced in the carrier gas treatment of vegetable oils, by treating the scum or sludge or a distillate from it with a lower aliphatic alcohol and an esterification catalyst to esterify fatty acids, the esters being then separated from the tocopherol by distillation. If desired the scum or sludge may be pretreated for instance with acids, alkalies or solvents. Suitable catalysts are sulphuric, hydrochloric and phosphoric acids. The treatment may be effected in inert gas or with the addition of a reducing agent such as zinc dust, iron, tin, stannous chloride and sodium hydrosulphite. Examples are given. The Provisional Specification contains an additional example of the treatment of a high vacuum distillate from corn oil.
After allocation, the control group will receive access to the DECIMS-Wiki for a two-week period. DECIMS (Decision coaching in MS)-Wiki (www.wiki2.kkn-ms.de) is an evidence-based patient information website focusing multiple sclerosis immunotherapies. Afterwards, primary and secondary outcome measures will be obtained. In a next step, patient will be asked for their treatment decision in a physician encounter.
Gallbladder cancer is a rare but fatal malignancy. However, the mechanisms underlying gallbladder carcinogenesis and its progression are poorly understood. The function of m6A modification and its regulators was still unclear for gallbladder cancer. The current study seeks to investigate the function of YTH m6A RNA-binding protein 1 (YTHDF1) in gallbladder cancer. Transcriptomic analysis and immunochemical staining of YTHDF1 in gallbladder cancer tissues revealed its upregulation compared to paracancerous tissues. Moreover, YTHDF1 promotes the proliferation assays, Transwell migration assays, and Transwell invasion assays of gallbladder cancer cells in vitro. And it also increased tumour growth in xenograft mouse model and metastases in tail vein injection model in vivo. In vitro, UHRF1 knockdown partly reversed the effects of YTHDF1 overexpression. Mechanistically, dual-luciferase assays proved that YTHDF1 promotes UHRF1 expression via direct binding to the mRNA 3'-UTR in a m6A-dependent manner. Overexpression of YTHDF1 enhanced UHRF1 mRNA stability, as demonstrated by mRNA stability assays, and Co-IP studies confirmed a direct interaction between YTHDF1 and PABPC1. Collectively, these findings provide new insights into the progression of gallbladder cancer as well as a novel post-transcriptional mechanism of YTHDF1 via stabilizing target mRNA.
PURPOSE:To obtain a Maillard reaction inhibitor, containing a flavonoid contained in Scutellariae Radix as a pharmacologically active ingredient and capable of inhibiting the formation itself of an Amadori transition reaction product which is a direct causative substance for forming intermolecular crosslinkages. between protein molecules in the Maillard reaction. CONSTITUTION:Scutellariae Radix is dipped in a mixture solution of water and a lower alcohol, preferably a mixture solution of 80-70wt.% methanol or ethanol based on 20-30wt.% water and warmed (preferably at 40-60 deg.C) to provide an extract solution. To the resultant extract solution, is added water in an amount of >=2 times based thereon. Alternatively, the alcohol is volatilized to reduce the concentration thereof to <=25wt./vol.% and afford an extract composed of a sparingly water-soluble deposited substance. The obtained extract is then contained as a pharmacologically active ingredient in the objective inhibitor. The aforementioned inhibitor is used for treating or preventing various diabetic complications or diseases of the same kind (e.g. atherosclerosis, cerebal angiopathy or senile cataract) caused by aging.
This study aims to measure the effect of urolithin A supplementation on endothelial function, cerebral blood flow regulation, and serum biomarkers of NO bioavailability and mitochondrial function in middle-aged adults with obesity. Briefly, 54 adults aged 40-64 years of age with a body mass index equal to or greater than 30 kg/m2 will be recruited to participate in a double-blind placebo-controlled parallel study for 4 weeks. Participants will be randomly assigned to intervention or control group. Those in the intervention group will consume 1,000 mg of urolithin A daily in the form of softgel capsules, whereas those in the control group will consume a placebo. Data collection will occur at baseline (day 0) and endpoint (day 28). The investigators will compare outcomes between control and intervention group. Researchers expect that urolithin A supplementation in middle-aged adults with obesity improves endothelial function and cerebral blood flow regulation, and that this improvement is accompanied by changes in biomarkers of NO bioavailability and mitochondrial function.